PLAT and diabetes mellitus: The underlying mechanisms remain to be determined and would be as follows: (1) compared with subjects without diabetes, those with diabetes had higher plasminogen activator inhibitor‐1 (PAI‐1) and tissue‐type plasminogen activator (t‐PA) levels, which indicated a disorder in the fibrinolytic system [19]; (2) the glucose‐lowering agents, such as metformin, may interact with antiplatelet drugs to reduce platelet activity [20].